




**The Ontario HIV Treatment Network**  
annual report  
2003

# OHTN 5th Annual Research Day

*Delta Chelsea Hotel, Toronto*

*November 28-29, 2002*



Mark Wainberg, Sean Rourke, Brian Cornelson, Ken Rosenthal, Stephen Squibb



Lynne Leonard, Liviana Calzavara




Dale Butterill, John Lavis



Robin Weir, Deborah Randall-Wood, Joan Lesmond



Erin MacDonald, Charu Kaushic, Amy Gillgrass, Tara Graham



Sean Hosein, Ron Rosenes



Esther Tharao, Lea Narciso

cover photo (from top left): Gary Rubin, Rob McKay, Brian Cornelson, Stephen Squibb, Carol Swantee, Owen Ryan, Brenda Done, Jennifer Furtney, Vicki Kett, Anita Rachlis, Patricia Balough, Karen Copeland, Lisa Bromley, Sean Rourke, Bob Leahy

## **MISSION STATEMENT**

*To be a collaborative network of excellence among consumers, providers and other stakeholders that provides leadership and develops and advances policy related to the optimal care and treatment of people living with HIV in Ontario. In so doing, the Ontario HIV Treatment Network (OHTN) strives to ensure timely access to state of the art health care, respect consumer options, ensure consumer and provider education and support, address emerging issues and seek appropriate funding in the treatment and management of HIV in Ontario.*

## **VISION**

*To ensure excellence in care and treatment of people living with HIV in Ontario, while respecting the rights of individuals to choice and confidentiality.*

## Letter from the Co-chairs

The OHTN was established five years ago as an initiative of the Ontario Ministry of Health and Long Term Care, and has become a major force in advancing research and clinical excellence in HIV/AIDS in Ontario and Canada. Through the hard work and dedication of the staff, volunteers and the many other stakeholders, we have made great progress in implementing the strategic programs that were established to fulfill our mission. These programs are the Investigator Driven Research Program (IDRP), the Priority Initiatives Program (PIP) and the HIV Information Infrastructure Project (HIIP).

A key contributor to our accomplishments over these past five years has been Patricia Balogh, the Executive Director of the OHTN since its inception. Patricia left the OHTN in February 2003 and her tremendous contribution to the development of the OHTN is recognized and very much appreciated. We are fortunate to have retained Dr. Jay Browne, former Director of the AIDS Bureau, as interim Executive Director pending completion of our recruitment for the position of Executive Director.

There have been other staff changes at the OHTN over the past year as well. Four staff positions were eliminated in order to devote more funds to research activities. The role of Dr. Ahmed Bayoumi as Director of Science was modified to permit better congruency with his other responsibilities; he is now Director of Research.

Research activities have flourished in the Investigator Driven Research Program, coordinated by Tom Fleming and Carol Major. Research generated within the OHTN from HOOD data as well as independent research funded by OHTN was well received at national and international symposia, reflecting the maturation of the organization's work. IDRP's Scientific Review Committee comprises renowned researchers from Canada, the United States and abroad and is headed by Dr. Mark Wainberg of Montreal. The OHTN continues to support promising upcoming researchers through its various scholarship awards. The Annual Research Day, led by Dr. Sean Rourke, proved to be a tremendous success.

The Priority Initiatives Program, coordinated by William Lau, has evolved from its inception as a stakeholder driven program to its present role of funding research proposals on priority areas targeted by the OHTN in consultation with its stakeholders.

The HIV Information Infrastructure Project has made great advances under the leadership of Bob Duck. HIIP has progressed through the development and testing phases and is now being used in major clinical sites in Ottawa and Toronto. The implementation of the HIIP modules into more HIV clinical sites is moving into high gear over the next few years, further enriching the research database built on the legacy of the HOOD database.

Based on the solid foundation of our first five years, we look forward to strengthening our mission and our contribution to HIV/AIDS care and research. We plan to initiate an external evaluation and develop a strategic plan over the next year in order to enhance the success of the organization.

We look forward to your continued support as we continue to mature as an organization and enhance our capacity to contribute to the lives of people with HIV/AIDS.

~ Dr. Brian Cornelson ~ Stephen Squibb

Co-chairs, Board of Directors

## Letter from the Interim Executive Director

I have been Interim Executive Director since May 27th, 2003. It has been a personal learning experience to bear witness to the present status of an organization that I helped initiate. It is a real privilege for me to now be part of a program that I saw as a dream of PHA leadership for many years. Sadly, some are no longer with us except in spirit and memory.

All of our stakeholders including the staff and volunteers can be very proud of the work of the Ontario HIV Treatment Network (OHTN). Major achievements for 2002-2003 include:

- ▶ a successful fifth annual Research Day;
- ▶ numerous abstracts presented at national and international conferences;
- ▶ the creation and deployment of a Microsoft SQL Server version of the HIIP Clinical Management System (CMS) software;
- ▶ the completion of the comprehensive HIIP Research Policies; and
- ▶ the Ambassador Committee presented its evaluation of antiretroviral utilization in Ontario at the annual conference of the Canadian Association for Population Therapeutics.

While some of the programs are in transition and face significant challenges, I believe all of the OHTN programs are on track and solidly moving forward. This annual report reflects my positive comments.

Future work, in conjunction with the Executive Committee, will focus on the OHTN Board development and membership selection process. Evaluation and strategic planning processes are key to shaping the OHTN's continued success.

In conclusion, I am grateful for the opportunity to be the Interim Executive Director.

A handwritten signature in black ink, appearing to read "Jay Browne". The signature is fluid and cursive, with a large initial "J" and a long, horizontal stroke at the end.

Jay Browne, Interim Executive Director

## OHTN Volunteers 2002-2003

*The following volunteers from across Ontario represent the Ontario HIV Treatment Network's five stakeholder groups: people living with HIV, researchers, clinicians, AIDS service organizations, and government. The work of the OHTN is made possible through the vital contribution of our dedicated volunteers. If we have omitted any name in error, we apologize.*

**Note:** All volunteers are Ontario-based unless otherwise noted.

### BOARD OF DIRECTORS

Dr. Brian Cornelson (Co-Chair)  
Stephen Squibb (Co-Chair)  
Dr. Lisa Bromley  
Dr. Karen Copeland  
Brenda Done  
Jennifer Furtney  
Dr. John Goodhew  
Vicki Kett  
Rob MacKay  
Frank McGee  
Dr. Anita Rachlis  
Dr. Sean Rourke  
Owen Ryan  
Carol Swantee  
Ilona Torontali

### FINANCE COMMITTEE

Vicki Kett  
Bob Leahy  
John Mountain  
Owen Ryan  
Stephen Squibb

### EXECUTIVE COMMITTEE

Dr. Brian Cornelson  
Brenda Done  
Bob Leahy  
Stephen Squibb

### HIIP ADVISORY COMMITTEE

Dr. Don Kilby (Chair)  
Robert Desarmia  
Tony Di Pedé  
Mary Grondin  
Steve Harris  
Maggie Lopes  
Rob MacKay

Dr. Robert Remis  
Jackie Roberts  
Daniel Robillard (*deceased*)  
Jim Truax  
Pius White

### Ex-Officio Members

Mario Cordoba  
Mark Fisher  
Frank McGee  
Dr. Anita Rachlis  
Carol Swantee

### Corresponding Members

Brent Fraser  
Dr. Ken Rosenthal  
Larry Stump

### HIIP Research

#### Advisory Committee

Dr. Robert Remis (Chair)  
Dr. Ahmed Bayoumi  
Dr. Jim Brunton  
Maggie Lopes  
Dr. Peggy Millson  
Dr. Ted Myers  
Jackie Roberts  
Pius White  
Dr. Wendy Wobeser

### HIIP Research Policy

#### Working Group

Maggie Lopes (Chair)  
Dr. Ahmed Bayoumi  
Dr. Evan Collins  
Dr. Winston Husbands  
Dr. Carol Strike

### Legal Ethical Committee

Rob MacKay (Chair)



Dr. Ahmed Bayoumi  
Tony Di Pede  
Mary Grondin  
Dr. Don Kilby  
Rodney Kort  
Maggie Lopes

#### **Technical Requirements Committee**

Mark Fisher (Chair)  
Mario Cordoba  
Dr. Don Kilby  
Rob MacKay

#### **PRIORITY ADVISORY COMMITTEE**

Brenda Done (Chair)  
Dr. Lisa Bromley  
Jennifer Furtney  
Vicki Kett  
Carl Orr  
Dr. Stanley Read  
Owen Ryan  
Esther Tharao

#### **Active Living, Work and Health**

##### **Working Group**

Stephanie Nixon (Chair)  
Louise Binder, LLD (Hon)  
Pamela Bowes  
Ken King  
Don Phaneuf  
Dr. Greg Robinson  
Dr. Patty Solomon  
Robert Vanidour

##### **Ambassador Committee**

Dr. Anita Rachlis (Chair)  
Pamela Bowes  
Frank McGee  
Ilona Torontali

#### **Complementary Therapies**

##### **Working Group**

Laurette Lévy (Chair)  
Dr. Gordon Arbess  
Dr. Heather Boon  
Dr. Kymm Feldman  
Sean Hosein  
Dr. Debbie Kopansky-Giles  
Devan Nambiar  
Ron Rosenes  
Derek Thaczuk

##### **Emerging Technology**

##### **Working Group**

Dr. Stanley Read (Chair)  
Sean Hosein  
Dr. John Kim  
Dr. Colin Kovacs  
Francis Mandy  
Frank McGee  
Dr. Anita Rachlis  
Dr. Paul Sandstrom  
Carol Swantee  
Dr. Sharon Walmsley

##### **PHA's in Prison Working Group**

Matthew Perry (Chair)  
Anne Marie DiCenso  
Giselle Dias  
Sarah Flicker  
Dr. Peter Ford  
Dr. Eudice Goldberg  
Laverne Monette  
Heather J. Topps

#### **SCIENTIFIC REVIEW COMMITTEE**

Dr. Mark Wainberg (Chair) (Montreal)  
Dr. Karen Copeland (ex officio)

Dr. Sean Rourke (ex officio)

##### **Basic Science**

Dr. Alan Landay (Chicago)  
Dr. Richard Harrigan (Vancouver)  
Sean Hosein  
Dr. Mario Ostrowski

##### **Clinical Science**

Dr. Rodger Macarthur (Michigan)  
Dr. Anita Rachlis  
Deborah Randall Woods  
Dr. Fiona Smaill

##### **Epidemiology**

Dr. Chris Archibald  
Dr. Eduard Beck (Montreal)  
Dr. Robert Remis  
Esther Tharao

##### **Socio Behavioral**

Dr. Barry Adam  
Dr. Louise Balfour  
Dr. Thomas Patterson (California)  
Dr. Winston Husbands

##### **Research Day**

##### **Planning Committee**

Dr. Sean Rourke (Chair)  
Dr. Alan Cochrane  
Dr. Bill Flanagan  
Vicki Kett  
Dr. John Lavis  
Dr. Lynne Leonard  
Frank McGee  
Lea Narciso  
Stephanie Nixon  
Dr. Gregory Robinson  
Dr. Mark Wainberg (Montreal)  
Dr. Sharon Walmsley

# Investigator Driven Research Program

The Investigator Driven Research Program (IDRP) is unique among research funding bodies. The strong community voice and multi-disciplinary perspective are incorporated into the Scientific Review Committee's peer review process. While community participation is a fundamental principle for the OHTN, it is unusual for scientific review organizations to support full community participation in their review process. This year, every project funded by the IDRP met both the program's rigorous scientific and community involvement requirements. The OHTN is fortunate to have Dr. Mark Wainberg as Chair of the Scientific Review Committee, supported by a panel of national and international HIV researchers and community members, as well as more than seventy external reviewers.

The IDRP continues to be the major source of HIV research funding for Ontario researchers. After five years, projects are now beginning to produce substantial results. World-class scientists carry out projects spanning the range of science from social science/epidemiology to basic/clinical science. Social science and epidemiology projects included exploring social and risk networks of intravenous drug users, understanding the behaviours and beliefs of the East African communities, and HIV prevention research. Basic/clinical science examples included studying the impact of sexually transmitted diseases on HIV, understanding the immune system, and predicting patient response to specific therapies. There were more than thirty scientific presentations from OHTN supported scientists at the XIV International AIDS Conference.

The fifth annual Research Day held in November 2002 was an outstanding success! Under the excellent leadership of Dr. Sean Rourke, Chair of the Planning Committee, the event attracted more than 300 participants and 150 abstract submissions. A major focus of the meeting was knowledge transfer — facilitating the communication of research findings between researchers and the people who use the information. Knowledge transfer will help to improve practice or change policies.

In summary, the IDRP has implemented a comprehensive and inclusive approach to project selection and continues to support Ontario HIV scientists. We look forward to continuing the focus on knowledge transfer at Research Day 2003.

A handwritten signature in black ink, appearing to read 'Carol Major', with a stylized, cursive script.

Carol Major, Research Coordinator



# Investigator Driven Research Program funded research 2002-2003

*The following researchers were awarded funds by the IDRP between July 2002 and June 2003*

## RESEARCH OPERATING GRANT

**Dr. Johane Allard – \$475,573 (3 year)**

Non-alcoholic fatty liver disease (NAFLD) in HIV: The role of nutritional interventions

**Dr. Jonathan Angel – \$176,000 (2 year)**

Regulation of IL-7 Receptor (CD127) Expression and Function on Circulating CD8+ T Cell and Developing Thymocytes by HIV Infection

**Dr. Ahmed Bayoumi – \$66,600 (1 year)**

The Cost-Effectiveness of Treating People Living with HIV: A Program of Research

**Dr. Liviana Calzavara – \$259,546 (2 year)**

Understanding HIV/AIDS Issues in East African Communities in Toronto: A Survey of Health-related Behaviours, Beliefs, Attitudes and Knowledge

**Dr. Rolf P.G. van Heeswijk – \$92,600 (1 year)**

The value of ABCB1 genotyping as a tool to predict the pharmacokinetics of protease inhibitors

**Dr. Rupert Kaul – \$148,000 (2 year)**

Cellular immune control of HIV-1 in the genital tract of infected men and women

**Dr. Peggy Millson – \$98,550 (2 year)**

Exploring the Social and Risk Networks of Male and Female Injection Drug Users in Toronto

**Dr. Scott Gray-Owen – \$160,000 (2 year)**

Impact of Neisseria gonorrhea on HIV-1 Replication and Immunity

**Dr. Wendy Wobeser – \$191,984 (2 year)**

Lactic acid metabolism in persons

infected with HIV. Predicting abnormalities in lactate production and clearance related to treatment and liver disease and measuring the effect of vitamin supplementation and changes in therapeutic regimen

## CAREER SCIENTIST AWARDS

**Dr. Peggy Millson – \$71,500/year (2 year)**

Epidemiological and Behavioural Studies of Injection Drug Users at Risk for HIV/AIDS in Ontario

**Dr. Ted Myers – \$71,500/year (5 year)**

Multi-dimensional Understanding of Responses to the Changing HIV/AIDS Epidemic: Community Contexts, Sexual and Drug Use Risk Behaviour and Interventions

## POSTDOCTORAL FELLOWSHIPS

**Dr. Julie Maggi – \$48,500/year (2 year)**

The impact of personality characteristics on adherence to medication treatment in HIV disease

**Dr. Colleen Millikin – \$38,500/year (2 year)**

Neurocognitive functioning in HIV/AIDS: Impact of HAART and time-course of response

**Dr. Jin Su – \$48,500/year (2 year)**

Correlation of CTL diversification with AIDS progression in DNA/MVA Vaccinated Macaques

**Dr. Jill Tinmouth – \$48,500/year (1 year)**

The role of lactose intolerance in HIV-related chronic non-infectious diarrhea

## SCHOLARSHIP AWARDS

**Dr. Rolf P.G. van Heeswijk – \$51,500/year (5 year)**

The value of ABCB1 genotyping as a tool to predict the pharmacokinetics of protease inhibitors

**Dr. Lynne Leonard – \$51,500/year (5 year)**

HIV and Hepatitis C Virus Co-Infection among Injection Drug Users: Directions for Prevention

## STUDENTSHIP AWARDS

**Agatha Komsic – \$19,530/year (2 year)**

Regulation of IL-7 Receptor (CD127) Expression on Circulating CDB + T Cells

**Natasha Christie – \$19,530/year (2 year)**

Understanding the Viral and Immunological Significance of CTL Epitopes in HIV Infection

**Kim Marsh – \$19,530/year (2 year)**

Sam68DeltaC: Molecular mechanisms of REV inhibition

**Reza Nazari – \$19,530/year (2 year)**

A novel gene therapy strategy inactivation of HIV-1 Provirus DNS

**Kelly O'Brien – \$19,530/year (2 year)**

Disability and HIV/AIDS: Evaluation of an instrument to address body structure/function, activity and participation for people living with HIV/AIDS

**Erin Warriner – \$19,530/year (2 year)**

Endocrine and immune correlates of neurocognitive impairments in HIV/AIDS

## Priority Initiatives Program

The Priority Initiatives Program (PIP) supports time-limited projects that fall within the OHTN mandate and are consistent with the priorities as identified by our stakeholders through the various working groups and committees.

In 2002 - 2003, PIP funded 16 projects in the total amount of \$855,867. Our comprehensive approach to addressing priority issues, by including academic and community-based initiatives, is one of the unique characteristics of PIP. The Priority Advisory Committee also demonstrated leadership in dealing with emerging priorities that included funding of projects on counseling for injection drug users and on HIV-positive parents from endemic countries.

The Ambassador Committee presented its recently completed evaluation of antiretroviral utilization in Ontario (1998 - 2002) at the annual conference of the Canadian Association for Population Therapeutics in Quebec City. The Committee also widened its consultations with stakeholders to address issues related to reforming the current funding and distribution arrangements through Ontario's Special Drugs Program for the antiretroviral drugs: AZT, ddI and ddC.

PIP takes a strong role in initiating community relevant projects that aim to impact both policy and practice. In 2003, PIP will restructure in response to the newly released "Proposed HIV/AIDS Strategy for Ontario to 2008". The new structure will consist of three streams:

- ▶ Care and Treatment;
- ▶ Education and Prevention; and
- ▶ Health Services and Access to Care.

The determinants of health will inform all three streams. This new structure will allow for a more comprehensive process in addressing emerging priority issues in Ontario.

I would like to take this opportunity to thank Brenda Done (Chair of the Priority Advisory Committee) and all our volunteers for their expertise, dedication and contribution.

A handwritten signature in black ink, appearing to read "William Lau".

William Lau, PIP Coordinator

## Priority Initiatives Program funded research 2002-2003

*The following projects were awarded one-time funding by PIP between April 2002 and March 2003*

**Dr. Beverley Antle – \$78,702**

Worry, Guilt and Loss: Exploring the needs and concerns of HIV-positive parents from endemic countries

**Dr. Lizanne Béique – \$100,000**

Internet-Based Post-Marketing Surveillance System for Patients with HIV/AIDS

**Glen Brown and Associates – \$10,000**

People with HIV/AIDS Issues Relating to Ontario Disability Support Program: A Policy Paper

**Glen Brown and Associates – \$2,247**

Creating, funding, hosting and supporting a provincial advocate/ombudsperson for issues relating to the Ontario Disability Support Program: A Feasibility Study

**Glen Brown and Associates – \$18,743**

Improving and Accessing Ontario Disability Support Program for PHAs: A Strategy Conference

**Giselle Dias, Todd Minerson – \$15,000**

The impact and accessibility of communities and prison services for male prisoners in Ontario: Protocol development

**Giselle Dias, Gurpreet Singh Johal – \$200,000**

HIV/AIDS & Hepatitis C Research Study for Men in Federal Institutions in Ontario

**Dr. Susan King – \$100,000**

Perinatal exposure to antiretroviral therapy in infants born to HIV infected mothers: evaluation of toxicity using mitochondrial DNA and lactate levels

**Dr. Debbie Kopansky-Giles – \$36,625**

Collection of Complementary and Alternative Medicine (CAM) Treatment Data for the HIIP (HIV Information Infrastructure Program): A Pilot Project

**Dr. Clifford Lingwood – \$25,000**

Therapeutic exploitation of the role of the glycolipid, globotriaosyl ceramide, in HIV infection

**Edward Mills – \$25,000**

HIV/AIDS Natural Treatment (HANT) Database and Linkage Project

**Dr. Peggy Millson – \$27,000**

Development and delivery of community-based para-professional

counselling for injection drug users living with or at high risk for HIV/AIDS

**Dr. Patty Solomon, Dr. Dale Guenter – \$84,000**

Prevalence of Participation and Activity Limitations in Person with HIV/AIDS in Ontario

**Dr. Rolf P. G. van Heeswijk – \$63,750**

The effects of co-administration of carotenoids on the pharmacokinetics of protease inhibitors in HIV-1-infected patients

**Dr. Rolf P. G. van Heeswijk – \$25,000**

Development of a bioanalytical method for measurement of the intracellular concentrations of protease inhibitors

**Dr. Sharon Walmsley – \$44,800**

Development and clinical assessment of a new T-20 genotypic resistance assay

# HIV Information Infrastructure Project

The HIV information Infrastructure Project (HIIP) made dramatic progress on all fronts in 2002-2003:

- ▶ Development
- ▶ Beta Testing
- ▶ Implementation Planning
- ▶ Training
- ▶ HOOD – HIIP Transition
- ▶ Research

Momentum is building as we move into the active recruitment and province-wide implementation phase of the HIIP Clinical Management System (CMS).

## **Development:**

Development of the Microsoft SQL Server version of the HIIP CMS software was completed during 2002-2003. Significant software development milestones were achieved. We look forward to completing the remaining development tasks and initiating full deployment in 2003-2004.

## **Beta Testing:**

Beta testing took some giant steps forward during the past year at all three sites:

- ▶ the University of Ottawa Health Services, Ottawa;
- ▶ Yonge-Eglinton Medical Centre, Toronto; and
- ▶ Sunnybrook and Women's College Health Sciences Centre, Toronto.

These beta sites represent the different HIV clinical practice models in the province: a large university-based clinic, a primary care physician group, and a hospital-based outpatient clinic. Lessons learned from this implementation provided valuable insights for our plan to roll out across the province.

## **Implementation Planning:**

The implementation plan was approved by the HIIP Advisory Committee in 2002-2003. The plan outlines a systematic approach for implementation in over 100 sites province-wide.

## **Training:**

The OHTN initiated the creation of supplementary training materials and expanded its scope to include primary training and materials. Our experience with testing demonstrated the importance of training to the overall success of the project.

**HOOD – HIIP Transition:**

The HIV Ontario Observational Database (HOOD), on which the foundation of the HIIP Project is built, remains a vital source of information for active current research in Ontario. A transition plan for the conversion of the HOOD database to the Central Research Database (CRD) has been initiated and will be implemented in tandem with HIIP site recruitment.

**Research:**

The research team within the HIIP has had another successful year. The HIIP research team, in collaboration with other Ontario researchers, presented numerous abstracts at national and international conferences. In addition to this work, we maintain the integrity of the HOOD data, provide reports to our stakeholder community, and respond to data requests from researchers.


The HOOD continues to expand and actively follows just over 2700 persons living with HIV/AIDS in Ontario. Adverse events information has been collected for approximately 2100 HOOD participants.

The HIIP research staff hosted a workshop for HOOD data collectors and data entry staff on maintaining data quality for research. The sessions focused on standardization of data collection and methods to ensure the integrity of the HOOD data.

July 2002 brought the first issue of the HIIP Research Update, a regular series of reports based on the data collected as part of the HOOD project. Cover stories have focused on topics relevant to our stakeholders: viral load and CD4 count trends in Ontario, and adverse event distribution in Ontario. We have also provided customized outputs to clinics that have contributed data to the HOOD project.

The HIIP Research policies were approved by the OHTN Board of Directors in March 2003. The policies are the product of a process involving a working group of stakeholder representatives. The Research team is now working on the implementation phase of the policies.

I would like to take this opportunity to thank all our volunteers for their commitment and contribution. The passing of our valued colleague Daniel Robillard (HIIP advisory committee member) this year, has reminded us all of the importance and urgency of the HIIP project to HIV research and the clinical management of HIV in Ontario.

A handwritten signature in black ink, appearing to read "Robert Duck", with a long, sweeping horizontal line extending to the right.

Robert Duck, Director of HIIP

# HIV Information Infrastructure Project research 2002-2003

*The following research projects were conducted by internal staff and external collaborators*

*10th CONFERENCE ON  
RETROVIRUSES AND  
OPPORTUNISTIC INFECTIONS 2003*

**Gender is Associated With  
Virologic Rebound and CD4 Cell  
Increases in Those Initiating Highly  
Active Antiretroviral Therapy: An  
Observational Study**

T. Forte, A.M. Bayoumi, P. Millson,  
P. Villeneuve, R.S. Remis, C. Major

*STATISTICAL SOCIETY OF  
CANADA ANNUAL MEETING 2003*

**Using A Matched-Cohort In Order  
To Validate The Effectiveness Of An  
Intervention In HIV Routine Practice**

C.M. Goia, A. M. Bayoumi, S. Gardner

*E - HEALTH 2003: A CATALYST  
FOR CHANGE*

**Privacy and Security of Electronic  
Patient Records in Changing Times**  
(oral presentation)

R. Hudder

**How to Customize Implementations  
in a Large-scale Clinical  
Management System Rollout**

K. Roshan, R. Hudder

*CANADIAN ASSOCIATION FOR  
HIV RESEARCH (CAHR) 2003*

**Community-Based Research  
and the HIIP/HOOD Database**

A.L.E. Andrews, L.A. Narciso,  
C.M. Goia, T. Forte, L. Brown,  
A.M. Bayoumi

**Representativeness of the HIV  
Ontario Observational Database  
(HOOD)**

T. Forte, A. M. Bayoumi, R. S. Remis,  
C. Swantee, A. Andrews, C.M. Goia,  
P. Millson, A. Rachlis, G. Robinson

**Differences Between Men and  
Women in Adverse Events After  
Initiating Protease Inhibitor  
Therapy**

T. Forte, A. M. Bayoumi, K. Yemm,  
P. Millson, A. Rachlis, G. Robinson

**The Imputation Of Missing  
Date Values In Antiretroviral  
Medication Data**

C.M. Goia, S. Gardner, A. Andrews,  
T. Forte, G. Robinson, A. Rachlis,  
A.M. Bayoumi

**Data Considerations When  
Converting From Manual Extraction  
To Electronic Extractions**

R. Hudder

**Effects of Electronic Patient Record  
(EPR) Design on an Observational  
Research Database**

R. Hudder

**How To Get Clinicians To Accept  
the Electronic Medical Record**

Z. Lee, R. Hudder

**Adverse Events – Data Capture  
for Research**

M. Ostan, K. Yemm

**Review of Antiretroviral Utilization  
In Ontario: Impact on Policy**

A. Rachlis, C. Jones, C. Major,  
R. Remis, B. Marshall, L. Tennant,  
I. Torontali, C. Marshall, P. Balogh,  
P. Bowes, F. McGee

**How Policy Decisions Made  
for the Implementation of a HIV  
Specific Clinical Management  
System Affect All Patients**

K. Roshan



## OHTN Staff

*The following are OHTN's staff  
in our three program areas:  
Investigator Driven Research  
Program (IDRP); Priority Initiatives  
Program (PIP); and HIV  
Information Infrastructure Project  
(HIIP) – including the HIV Ontario  
Observational Database (HOOD).*

### **INTERIM EXECUTIVE DIRECTOR**

Jay Browne

### **EXECUTIVE DIRECTOR (to Feb 03)**

Patricia Balogh

### **Amy Andrews**

research assistant, HIIP

### **Susan Barruch**

admin coordinator

### **Dr. Ahmed Bayoumi**

director of science, HIIP (to Jul 02)

### **Linda Brown**

research admin assistant, HIIP

### **Elaine Coyle**

admin assistant, executive director  
(to Mar 03)

### **Beverly Deutsch**

admin assistant, PIP

### **Robert Duck**

director, HIIP

### **Tom Fleming**

research administrator, IDRP

### **Tonia Forte**

research assistant, HIIP

### **Renée Fournier**

admin assistant, communications  
(to Mar 03)

### **Cristina Goia**

biostatistician, HIIP

### **Gerrardus Heddema**

user acceptance tester, HIIP  
(to Dec 02)

### **Paul Henman**

project manager, HIIP

### **Robert Hudder**

database administrator, HIIP

### **Teij Janki**

IT coordinator

### **William Lau**

coordinator, PIP

### **Zun Lee**

clinic relations coordinator, HIIP

### **Rose Lising**

program assistant, IDRP

### **Carol Major**

research coordinator, IDRP

### **Peter Marchand**

financial coordinator

### **Michelle Ostan**

research & informatics  
coordinator, HIIP

### **Kam Roshan**

business process analyst, HIIP

### **Chelvi Srishankar**

user acceptance tester, HIIP

### **Sherine Sterling**

admin assistant, HIIP (to Mar 03)

### **Polly Thompson**

communications coordinator  
(to Mar 03)

### **Ann Toth**

help desk coordinator, HIIP

### **Sergiy Tyshchenko**

programmer

### **Misa Yoshizaki**

receptionist

### **HOOD Data Entry Team**

Kevin Challacombe

Joe Sorbara

Kevin Yemm

### **HOOD Data Collectors**

Daryl Bell

Fran Clark

Brenda Done

Lisa Green

Gail Howlett

Nancy McFarland

Jane McKinley

Anja McNeil

Cathy Parent

Pat Rivet

Andrea Sharp

Suzanne Sharples

Beth Watson-Brooker

# Financial Statement 2002-2003

*As Interim Chair, I am pleased to submit the audited statements of the OHTN for fiscal year 2002 - 2003. I wish to thank the members of the Finance Committee for their hard work and dedication to the vision of the OHTN.*

~ Vicki Ridout Kett


**Note:** These statements were audited by PricewaterhouseCoopers and approval from the OHTN Board of Directors is still pending.

	2003	2002
	\$	\$
<b>ASSETS</b>		
<b>Current assets</b>		
Cash	1,430,351	1,197,964
Accounts receivable	39,602	83,485
Prepays	15,569	13,605
	1,485,522	1,295,054
<b>PROPERTY, PLANT AND EQUIPMENT</b>	115,060	108,344
	1,600,582	1,403,398
<b>LIABILITIES</b>		
<b>Current liabilities</b>		
Accounts payable and accrued liabilities	1,431,055	1,091,904
Deferred revenue	115,060	108,344
	1,546,115	1,200,248
<b>NET ASSETS</b>		
<b>Net assets invested</b>		
in property, plant and equipment	115,060	108,344
Unrestricted net assets (deficit)	(60,593)	94,806
	54,467	203,150
	1,600,582	1,403,398


	2003	2002
<b>REVENUE</b>	\$	\$
Grant from AIDS Bureau	8,000,000	7,865,802
Amortization of deferred revenue	77,161	587,657
	8,077,161	8,453,459
Interest	47,725	100,060
	8,124,886	8,553,519
<b>EXPENDITURES</b>		
Priority Initiatives Program	1,037,823	1,057,425
Investigator Driven Research Program	2,901,433	2,824,006
HIV Information Infrastructure Project and HIV Ontario Observational Database	1,804,659	1,849,995
Salaries and benefits	1,880,835	1,568,785
Office administration and rent	368,508	462,501
Amortization	77,161	587,657
	8,070,419	8,350,369
<b>SURPLUS OF REVENUE OVER EXPENDITURES</b>	54,467	203,150
<b>DIRECT DECREASE IN NET ASSETS</b>	(203,150)	(563,886)
<b>NET ASSETS – BEGINNING OF YEAR</b>	203,150	563,886
<b>NET ASSETS – END OF YEAR</b>	54,467	203,150

# OHTN Resource Allocation


*How Our Dollars Are Spent*




*HIV Information Infrastructure Program*




*Investigator Driven Research Program*



*Priority Initiatives Program*



## OHTN Staff and Volunteers



(from left): Teij Janki, Chelvi Srishankar, Linda Brown, Zun Lee, Paul Henman, Kam Roshan, Beverly Deutsch, Rose Lising, Misa Yoshizaki, Ann Toth



(from left): Beth Watson-Brooker, Jane McKinley, Joe Sorbara, Andrea Sharp, Kevin Yemm, Kevin Challacombe, Lisa Green, Fran Clark, Brenda Done, Pat Rivet, Robert Hudder, Michelle Ostan, Sergiy Tyshchenko



William Lau, Robert Duck, Peter Marchand, Susan Barruch, Frank McGee, Jay Browne



Cristina Goia, Kam Roshan



The Ontario HIV Treatment Network  
1300 Yonge Street, Suite 308  
Toronto, Ontario  
Canada M4T 1X3  
T 416 642 6486  
T 1 877 743 6486  
F 416 640 4245  
[www.ohtn.on.ca](http://www.ohtn.on.ca)

**The Ontario HIV Treatment Network is funded by the AIDS Bureau, Ontario Ministry of Health and Long Term Care.**